Navigation Links
ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe
Date:7/28/2014

MUNICH, July 28, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and other chronic respiratory conditions, has won a permanent injunction in Germany against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales of infringing headgear used on APEX WiZARD 210 and 220 masks.  The judgment was entered by the Regional District Court in Munich, is appealable, and applies throughout Germany. 

The permanent injunction continues a preliminary injunction that was entered by the same court on Nov. 12, 2013.  The court rejected APEX's request to stay the injunction and its challenge to the validity of ResMed's patent.  The judgment also requires APEX to forfeit its inventory of infringing products, to report on its sales of the infringing products, and to pay damages to ResMed.ResMed has also filed separate patent infringement lawsuits in the same court seeking damages and permanent injunctions to stop infringement of other ResMed patents. The trials of those cases will occur in the fall of 2014.  The additional accused products are:

  • The APEX iCH and XT Fit CPAP devices
  • The APEX WiZARD 210 and WiZARD 220 masks
  • "ResMed has a global business built on its investment in research and developments, resulting in products sold worldwide that excel in performance, quality and comfort," said David Pendarvis, ResMed global general counsel and chief administrative officer. "We will continue to defend our investment in intellectual property and pursue all legal remedies to prevent infringement in any country where that infringement exists."

    About ResMed: ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.  Contacts:
    For News Media For InvestorsGretchen Griswold

    Agnes LeeDirector, Global Corporate CommunicationsSenior Director, Investor RelationsO: 858-836-6789

    O: 858-836-5971news@resmed.com

    investorrelations@resmed.com


    '/>"/>
    SOURCE ResMed Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents
    2. ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results
    3. ResMeds New Nasal Pillows System is Our Quietest Yet; Ultra-light AirFit P10 Packs Powerful Performance in Just over 1.5 Ounces
    4. ResMed Announces Conference Call And Webcast To Discuss Second Quarter 2014 Results
    5. BMC to protect its rights in patent fight with ResMed
    6. Apex reagiert energisch auf ResMed Patentklage
    7. ResMed Receives Injunctions against APEX and BMC in Germany, Continues Enforcement of Patents in Europe
    8. ResMed Inc. Announces Record Financial Results For The Quarter Ended September 30, 2013
    9. ResMeds New Nasal Mask Sets the Bar for Comfort and Performance
    10. ResMed Patent Infringement Case Against BMC Advances: International Trade Commission Agrees to Investigate
    11. Apex Fights Back Against ResMeds Patent Litigation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/23/2017)... , Feb. 23, 2017   SeraCare Life ... global in vitro diagnostics manufacturers and clinical laboratories, ... "Catalyzing Implementation of NGS-Based Tests" to be hosted ... 2017 at 11am Eastern Standard Time (US). ... highlight the need for improved performance and global ...
    (Date:2/23/2017)... -- ML Capital Group, Inc. (USOTC: MLCG) today announced ... , a Colorado -based cannabis tourism company. ... (USOTC: PURA) to enter Colorado,s $19 billion ... Tours acquisition announced today is intended to accelerate MLCG,s ... ...
    (Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
    Breaking Medicine Technology:
    (Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an exciting, new, interactive publication where generations converge and explore the world from ... their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find ...
    (Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
    (Date:2/23/2017)... RYE, New York (PRWEB) , ... February 23, 2017 , ... ... to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, ... the 30 clinical sites already enrolling children across the United States. , “There ...
    (Date:2/22/2017)... East Setauket, New York (PRWEB) , ... February ... ... the main floor entrance and lobby of a new healthcare contact center in ... gleaming results. , One of the nation’s largest healthcare systems recently invested $51 ...
    (Date:2/22/2017)... Los Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... medical detox treatment to the thousands of individuals who have recently fallen victim to ... accredited hospital in Orange County, California, where they are free from the shame, ...
    Breaking Medicine News(10 mins):